Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $41.02 in the prior trading day, Xenon Pharmaceuticals Inc (NASDAQ: XENE) closed at $39.42, down -3.90%. In other words, the price has decreased by -$3.90 from its previous closing price. On the day, 0.68 million shares were traded. XENE stock price reached its highest trading level at $41.24 during the session, while it also had its lowest trading level at $39.37.
Ratios:
Our goal is to gain a better understanding of XENE by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 23.27 and its Current Ratio is at 23.27. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on October 01, 2024, initiated with a Buy rating and assigned the stock a target price of $53.
On January 04, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $62.
On December 08, 2023, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $63.Robert W. Baird initiated its Outperform rating on December 08, 2023, with a $63 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 08 ’24 when GAROFALO ELIZABETH A. sold 2,092 shares for $45.69 per share. The transaction valued at 95,583 led to the insider holds 0 shares of the business.
ROBIN SHERRINGTON sold 7,137 shares of XENE for $330,290 on Mar 07 ’24. The EVP, Strategy & Innovation now owns 8,398 shares after completing the transaction at $46.28 per share. On Mar 07 ’24, another insider, GANNON STEVEN, who serves as the Director of the company, sold 13,000 shares for $46.28 each. As a result, the insider received 601,615 and left with 2,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XENE now has a Market Capitalization of 2986636288 and an Enterprise Value of 2275134720.
Stock Price History:
Over the past 52 weeks, XENE has reached a high of $50.99, while it has fallen to a 52-week low of $27.99. The 50-Day Moving Average of the stock is -1.42%, while the 200-Day Moving Average is calculated to be -6.33%.
Shares Statistics:
The stock has traded on average 366.62K shares per day over the past 3-months and 364730 shares per day over the last 10 days, according to various share statistics. A total of 75.37M shares are outstanding, with a floating share count of 73.82M. Insiders hold about 2.56% of the company’s shares, while institutions hold 96.41% stake in the company. Shares short for XENE as of 1726185600 were 3595318 with a Short Ratio of 9.81, compared to 1723680000 on 3338326. Therefore, it implies a Short% of Shares Outstanding of 3595318 and a Short% of Float of 4.78.
